Claimed effect · Lixisenatide

Does Lixisenatide help with motor progression in early Parkinson's disease?

B
Grade B — probable, not settled1 phase 2 RCT (n=156, 12 mo) · effect size: small
Short answerProbable, not settled. Human data exist (1 phase 2 RCT (n=156, 12 mo)) and mostly agree, showing a small effect — but too few, too small, or not yet peer-reviewed for a firm answer. LIXIPARK: motor scores were essentially unchanged on lixisenatide and worsened by three points on placebo over a year — a statistically clear but clinically modest difference, in a trial too small and short to establish disease modification.

What the studies show

LIXIPARK: motor scores were essentially unchanged on lixisenatide and worsened by three points on placebo over a year — a statistically clear but clinically modest difference, in a trial too small and short to establish disease modification.

“At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007).”

Verbatim, from the abstractMeissner WG, et al. Trial of lixisenatide in early Parkinson's disease (LIXIPARK). N Engl J Med, 2024;390:1176–1185

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1
    Meissner WG, et al. Trial of lixisenatide in early Parkinson's disease (LIXIPARK).N Engl J Med, 2024;390:1176–1185156 randomised, 12 months. NCT03439943.

In context

Lixisenatide is a short-acting GLP-1 receptor agonist derived from exendin-4, approved for type 2 diabetes since 2013 and now sold mainly in combination with insulin glargine. Its cardiovascular-outcomes trial in 6,068 people after a heart attack was neutral. In 2024 a French phase 2 trial found that a year of lixisenatide slowed motor progression in early Parkinson's disease by about three points on the standard scale, with nausea in nearly half. It is prescription-only; the standalone product has been withdrawn in some markets.

Lixisenatide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Lixisenatide proven to help with motor progression in early Parkinson's disease?
Not yet settled. 1 phase 2 RCT (n=156, 12 mo) — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
LIXIPARK: motor scores were essentially unchanged on lixisenatide and worsened by three points on placebo over a year — a statistically clear but clinically modest difference, in a trial too small and short to establish disease modification.
Is Lixisenatide approved for this?
Lixisenatide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Lixisenatide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 23 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →